Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale

BACKGROUND: Rituximab has become a standard treatment for non‐Hodgkin lymphoma. Clinical studies have demonstrated the efficacy of rituximab in combination with standard chemotherapies in the treatment of follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) patients. This non‐intervent...

Descripción completa

Detalles Bibliográficos
Autores principales: Dürig, Jan, Uhlig, Jens, Gerhardt, Anke, Ritter, Markus, Hapke, Gunnar, Heßling, Jörg, Staib, Peter, Wolff, Frieder, Krumm, Katja, von Weikersthal, Ludwig Fischer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939131/
https://www.ncbi.nlm.nih.gov/pubmed/36017743
http://dx.doi.org/10.1002/cam4.5160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939131/
https://www.ncbi.nlm.nih.gov/pubmed/36017743
http://dx.doi.org/10.1002/cam4.5160

Ejemplares similares